Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sitafloxacin + colistin + meropenem vs colistin + meropenem for multidrug-resistant Acinetobacter baumannii HAP/VAP
TCTR20221221001Phase 4Completed
- Sponsor
- Rajavithi Hospital
- Start
- Apr 2021
- Modality
- Small Molecules, Peptides
- Countries
- 1
01
Overview
Phase 4, randomised trial in pneumonia and multidrug-resistant Acinetobacter baumannii infection comparing Sitafloxacin + colistin + meropenem with Colistin + meropenem (2 arms). Started Apr 2021; status: completed.
02
Drugs
sitafloxacincolistinmeropenem
03
Conditions
pneumoniamultidrug-resistant Acinetobacter baumannii infection
Beyond the preview
Go deeper on TCTR20221221001.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on TCTR20221221001.